Drugs / AdHer-2/neu transduced dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00162929 | Jan 2005 → Jul 2009 | breast cancer | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdHer-2/neu transduced dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00162929 ↗ |
| Known as | AdHer-2/neu | “The purpose of this study is to determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of human autologous dendritic cells transduced by an...” NCT00162929 ↗ |
| Modality | Cell therapy | “human autologous dendritic cells transduced by an adenovector” NCT00162929 ↗ |